

Recent Advances in Bioanalytical Methods for Quantitative Determination of Drugs in Biological Matrices: A Comprehensive Review

Authors:

Radhika Nandigam¹, Prof. Kumaraswamy Gandla^{*2}

¹Research Scholar, Department of Pharmacy, Chaitanya Deemed to be University, Moinabad (Mandal), RangaReddy (Dist), Telangana 500075.

²Professor, Department of Pharmacy, Chaitanya Deemed to be University, Moinabad (Mandal), RangaReddy (Dist), Telangana 500075.

***Corresponding Author:**

Prof. Kumaraswamy Gandla

Dean and BoS Chairperson, Department of Pharmacy, Chaitanya Deemed to be University, Moinabad, Hyderabad, Telangana 500075. Email: drkumaraswamygandla@gmail.com

<https://doi.org/10.5281/zenodo.21771881>

Received: 15 July 2026, Accepted: 30 July 2026, Online First: 03 August 2026

ABSTRACT

Quantitative determination of drugs in biological fluids is fundamental to pharmaceutical research, clinical pharmacology, therapeutic drug monitoring, pharmacokinetic investigations, and regulatory submissions. Accurate measurement of drug concentrations in biological matrices such as plasma, serum, whole blood, urine, saliva, cerebrospinal fluid, and tissues is essential for evaluating drug absorption, distribution, metabolism, and excretion, assessing bioavailability and bioequivalence, optimizing dosage regimens, and ensuring drug safety and therapeutic efficacy. Over the past two decades, bioanalytical science has undergone remarkable advancements, transitioning from conventional analytical methods to highly sensitive and selective chromatographic and hyphenated techniques. Among these, high-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography (UHPLC), gas chromatography mass spectrometry (GC-MS), liquid chromatography tandem mass spectrometry (LC-MS/MS), high-resolution mass spectrometry (HRMS), and capillary electrophoresis mass spectrometry (CE-MS) have become indispensable tools for quantitative drug analysis. Efficient sample preparation remains a critical component of bioanalysis, with techniques such as protein precipitation, liquid-liquid extraction, solid-phase extraction, microextraction methods, and automated sample preparation significantly reducing matrix effects while improving analyte recovery, sensitivity, and reproducibility. Recent innovations, including microfluidic platforms, dried blood spot sampling, biosensors, nanotechnology-based analytical systems, high-resolution mass spectrometry, artificial intelligence-assisted data processing, and automated bioanalytical workflows, have further enhanced analytical performance, throughput, and reliability. In parallel, stringent bioanalytical method validation guidelines issued by regulatory authorities, including the International Council for Harmonisation (ICH M10), the United States Food and Drug Administration (US FDA), and the European Medicines Agency (EMA), have established standardized criteria for ensuring the accuracy, precision, selectivity, sensitivity, robustness, and reproducibility of bioanalytical methods. This comprehensive review critically discusses recent advances in bioanalytical techniques for the quantitative determination of drugs in biological fluids, emphasizing analytical principles, sample preparation strategies, hyphenated analytical technologies, bioanalytical method validation, regulatory expectations, and applications in pharmacokinetic, bioavailability, bioequivalence, toxicokinetic, and clinical studies. Furthermore, the review highlights current challenges, emerging trends, and future perspectives that are expected to shape the next generation of bioanalytical methodologies for pharmaceutical research and clinical applications.

Keywords: *Advanced bioanalytical techniques; Drug quantification; Biological fluids; LC-MS/MS; UHPLC-MS/MS; High-resolution mass spectrometry; Bioanalytical method validation; Pharmacokinetics; Therapeutic drug monitoring; Pharmaceutical analysis*

1. INTRODUCTION

Accurate quantification of drugs and their metabolites in biological fluids is a cornerstone of pharmaceutical research, clinical pharmacology, and therapeutic drug monitoring (TDM). The determination of drug concentrations in biological matrices provides essential information on the pharmacokinetic profile of therapeutic agents, including absorption, distribution, metabolism, and excretion (ADME). These pharmacokinetic parameters are fundamental for understanding the time course of drug action, evaluating systemic exposure, optimizing dosage regimens, and ensuring the safe and effective use of medicines. Reliable quantitative bioanalysis is also indispensable for assessing pharmacodynamic relationships, evaluating drug–drug interactions, and supporting dose optimization in diverse patient populations. Consequently, sensitive, selective, and reproducible bioanalytical methods have become integral to modern pharmaceutical sciences and clinical practice.^{1–8}

Therapeutic drug monitoring further underscores the importance of accurate bioanalytical measurements, particularly for drugs with narrow therapeutic indices, considerable pharmacokinetic variability, or concentration-dependent efficacy and toxicity. Examples include aminoglycoside antibiotics, antiepileptic drugs, immunosuppressants, anticancer agents, and certain cardiovascular medications. In such cases, maintaining plasma or serum drug concentrations within the therapeutic range is essential to maximize clinical efficacy while minimizing adverse drug reactions. Precise quantification of drug levels enables clinicians to individualize therapy, adjust dosing regimens, improve patient outcomes, and reduce the risk of treatment failure or toxicity. In addition, quantitative drug analysis plays a pivotal role in toxicological investigations, forensic analyses, and personalized medicine, where accurate determination of drug concentrations is essential for informed clinical decision-making.

1.1 Role of Bioanalytical Techniques in Drug Discovery and Development

Bioanalytical techniques are indispensable throughout the pharmaceutical product lifecycle, from early drug discovery to post-marketing surveillance. During the preclinical phase, bioanalytical methods are employed to characterize the pharmacokinetic and toxicokinetic properties of candidate molecules in experimental animal models, facilitating the assessment of systemic exposure, tissue distribution, metabolic pathways, and safety profiles. These investigations provide critical information for lead optimization, candidate selection, and dose projection before human clinical studies.

During clinical development, validated bioanalytical methods are used to quantify drugs, metabolites, and biomarkers in biological samples collected from

healthy volunteers and patients. These analyses support pharmacokinetic studies, bioavailability and bioequivalence evaluations, dose-escalation studies, food-effect investigations, and drug–drug interaction assessments. Quantitative bioanalysis also contributes to therapeutic drug monitoring, population pharmacokinetic modeling, pharmacodynamic evaluations, and biomarker-based clinical research. Furthermore, regulatory agencies require validated bioanalytical data to demonstrate the quality, reliability, and reproducibility of analytical results submitted in support of new drug applications, generic drug approvals, and biosimilar development. Consequently, robust and validated bioanalytical methods are essential for ensuring the successful development, regulatory approval, and clinical application of pharmaceutical products.^{9–12}

1.2 Common Biological Matrices Used for Drug Analysis

A variety of biological matrices are routinely employed for quantitative drug analysis, depending on the objectives of the pharmacokinetic, toxicological, or clinical investigation. Plasma and serum remain the most extensively used matrices because they directly reflect systemic drug exposure and are readily obtained during clinical studies. Plasma is generally preferred in pharmacokinetic investigations owing to the presence of anticoagulants and reduced processing time, whereas serum is frequently used in clinical chemistry and therapeutic drug monitoring.

Urine is another widely utilized biological matrix, particularly for evaluating drug excretion, metabolite profiling, renal clearance, and compliance monitoring. Owing to its non-invasive collection and relatively high analyte concentrations, urine is especially valuable in toxicological and forensic analyses. Saliva has emerged as an attractive alternative biological fluid for therapeutic drug monitoring because sample collection is simple, non-invasive, and suitable for repeated measurements. For several drugs, salivary concentrations correlate well with pharmacologically active free drug levels in plasma.

Specialized biological matrices such as cerebrospinal fluid (CSF), synovial fluid, tissue homogenates, bronchoalveolar lavage fluid, and vitreous humor are employed when assessing tissue distribution or site-specific drug exposure. In particular, CSF analysis is indispensable for evaluating the penetration of therapeutic agents across the blood–brain barrier and for developing treatments targeting central nervous system disorders.

Each biological matrix possesses distinct physicochemical characteristics, including differences in protein composition, lipid content, viscosity, pH, endogenous metabolites, and potential interfering substances. These matrix-specific factors may significantly influence analyte recovery, ionization

efficiency, extraction performance, and overall analytical accuracy. Matrix effects are particularly critical in mass spectrometry-based assays and may lead to ion suppression or enhancement if not properly controlled. Therefore, appropriate sample preparation strategies such as protein precipitation, liquid–liquid extraction, solid-phase extraction, and microextraction techniques combined with highly selective chromatographic and hyphenated analytical methods are essential to minimize matrix interference and ensure reliable quantitative results.^{13–15}

The continuous evolution of analytical instrumentation has transformed pharmaceutical bioanalysis from conventional chromatographic techniques to highly sensitive hyphenated platforms, including liquid chromatography tandem mass spectrometry (LC–MS/MS), ultra-high-performance liquid chromatography mass spectrometry (UHPLC–MS/MS), gas chromatography–mass spectrometry (GC–MS), and high-resolution mass spectrometry (HRMS). These advanced technologies provide exceptional sensitivity, selectivity, accuracy, and throughput, enabling the quantification of trace-level analytes in complex biological matrices. Alongside innovations in sample preparation, automation, microfluidics, biosensor technologies, artificial intelligence-assisted data analysis, and regulatory harmonization, these developments continue to expand the capabilities of modern bioanalysis and support advances in drug development, precision medicine, and clinical pharmacology. The following sections comprehensively review these bioanalytical techniques, their validation requirements, current applications, emerging technologies, and future perspectives for quantitative drug determination in biological fluids.

1.3 Evolution of Analytical Techniques: From Conventional Methods to Advanced Instrumentation

The field of bioanalysis has undergone remarkable transformation over the past few decades, driven by continuous advances in analytical instrumentation, separation science, and detection technologies. Early bioanalytical investigations primarily relied on conventional analytical techniques such as ultraviolet–visible (UV–Vis) spectrophotometry, colorimetric assays, fluorimetry, and thin-layer chromatography (TLC). These methods provided valuable qualitative and semi-quantitative information and formed the foundation of pharmaceutical analysis. However, their applicability in complex biological matrices was limited by inadequate sensitivity, poor selectivity, restricted dynamic range, and susceptibility to interference from endogenous compounds.

The introduction of high-performance liquid chromatography (HPLC) represented a major milestone in analytical science by significantly improving separation efficiency, analytical precision,

and reproducibility. HPLC enabled the reliable quantification of drugs and their metabolites in biological samples and rapidly became the preferred analytical platform for pharmaceutical research. Subsequent technological innovations, including ultra-high-performance liquid chromatography (UHPLC), enhanced chromatographic performance through the use of smaller particle-size columns and higher operating pressures, resulting in shorter analysis times, improved peak resolution, and increased analytical throughput.

A further breakthrough in bioanalysis occurred with the integration of chromatographic techniques and mass spectrometry (MS), leading to the development of hyphenated analytical platforms such as liquid chromatography mass spectrometry (LC–MS), liquid chromatography tandem mass spectrometry (LC–MS/MS), gas chromatography mass spectrometry (GC–MS), ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS), and high-resolution mass spectrometry (HRMS). These advanced techniques combine the superior separation capability of chromatography with the exceptional sensitivity, selectivity, and structural identification power of mass spectrometry. Consequently, they enable accurate quantification of drugs, metabolites, degradation products, and biomarkers at trace concentration levels in complex biological matrices while minimizing matrix interference.

Recent advances in analytical instrumentation have further expanded the capabilities of bioanalysis through the introduction of high-resolution accurate-mass spectrometry, quadrupole time-of-flight mass spectrometry (QTOF–MS), Orbitrap mass spectrometry, capillary electrophoresis–mass spectrometry (CE–MS), automated sample preparation systems, microfluidic platforms, ambient ionization techniques, and artificial intelligence-assisted data processing. These innovations have substantially improved analytical sensitivity, selectivity, speed, robustness, and data interpretation, enabling comprehensive pharmacokinetic, metabolomic, and biomarker studies. As a result, modern bioanalytical laboratories are now capable of high-throughput analysis with enhanced reliability, making advanced hyphenated analytical techniques indispensable tools in pharmaceutical research, clinical pharmacology, therapeutic drug monitoring, and regulatory bioanalysis.^{16–20}

1.4 Limitations of Earlier Analytical Methods

Although conventional analytical techniques played a crucial role in the early development of pharmaceutical analysis, several inherent limitations restricted their application in modern bioanalytical investigations. Spectrophotometric, colorimetric, fluorimetric, and thin-layer chromatographic methods generally lacked sufficient selectivity when applied to complex

biological matrices such as plasma, serum, urine, or tissue homogenates. The presence of endogenous biomolecules including proteins, phospholipids, lipids, and metabolites often caused significant analytical interference, leading to reduced accuracy and compromised quantitative performance.

Furthermore, many conventional analytical methods exhibited relatively low sensitivity, making them unsuitable for detecting drugs and metabolites present at nanogram- or picogram-level concentrations. Such limitations became increasingly important with the development of highly potent pharmaceuticals administered at low therapeutic doses. In many instances, extensive sample preparation procedures including multiple extraction, purification, and concentration steps were required to minimize matrix interference before analysis, increasing both labor intensity and the likelihood of analytical variability.

Additional drawbacks included limited chromatographic resolution, narrow linear dynamic ranges, inadequate specificity for structurally related compounds, and the inability to distinguish parent drugs from metabolites or degradation products. Conventional methods were also characterized by relatively long analytical run times, lower sample throughput, and limited automation, making them less suitable for large-scale pharmacokinetic, bioavailability, bioequivalence, and clinical studies.

These shortcomings, together with the increasing complexity of modern pharmaceutical compounds and evolving regulatory expectations, highlighted the need for more sensitive, selective, rapid, and reproducible analytical methodologies. Consequently, advanced hyphenated analytical techniques particularly LC–MS/MS, UHPLC–MS/MS, GC–MS, and HRMS have become the gold standard for quantitative drug analysis in biological fluids. Their superior analytical performance, combined with robust sample preparation strategies and standardized bioanalytical method validation procedures, has significantly improved the reliability and efficiency of pharmaceutical bioanalysis and continues to drive innovation in drug discovery, clinical research, and precision medicine.^{21–24}

1.5 Scope and Objectives of the Review

The present review aims to provide a comprehensive and critical overview of advanced bioanalytical techniques employed for the quantitative determination of drugs in biological fluids. Particular emphasis is placed on recent developments in sample preparation methodologies, chromatographic separation techniques, spectroscopic approaches, and hyphenated analytical platforms that have transformed modern bioanalysis. The review comprehensively discusses conventional and emerging analytical technologies, highlighting their analytical principles, instrumentation, advantages, limitations, and pharmaceutical applications.

Special attention is devoted to highly sensitive and selective hyphenated techniques, including liquid chromatography tandem mass spectrometry (LC–MS/MS), ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS), gas chromatography–mass spectrometry (GC–MS), high-resolution mass spectrometry (HRMS), and capillary electrophoresis–mass spectrometry (CE–MS), which have become indispensable tools in pharmacokinetic investigations, bioavailability and bioequivalence studies, therapeutic drug monitoring, toxicokinetic evaluations, and biomarker analysis. The review also addresses recent advances in sample preparation strategies, including protein precipitation, liquid–liquid extraction, solid-phase extraction, microextraction techniques, and automated sample processing, which are essential for minimizing matrix effects and improving analytical sensitivity and reproducibility.

Furthermore, emerging technologies such as microfluidic platforms, lab-on-a-chip systems, biosensors, nanotechnology-based analytical devices, ambient ionization techniques, artificial intelligence-assisted data analysis, and high-throughput automated bioanalytical workflows are critically evaluated with respect to their potential to improve analytical efficiency, sensitivity, and clinical applicability. In addition, current regulatory expectations for bioanalytical method validation, including the International Council for Harmonisation (ICH M10), the United States Food and Drug Administration (US FDA), and the European Medicines Agency (EMA), are discussed to provide a comprehensive perspective on quality assurance and regulatory compliance.

By critically evaluating established and emerging bioanalytical methodologies, their advantages, limitations, and practical applications, this review aims to provide pharmaceutical scientists, analytical chemists, clinical researchers, and regulatory professionals with a comprehensive understanding of current bioanalytical strategies for accurate drug quantification in biological matrices while highlighting future opportunities for innovation in pharmaceutical analysis.

2. Biological Matrices Used for Drug Quantification

Quantitative determination of drugs in biological systems requires the analysis of complex biological matrices containing numerous endogenous components, including proteins, lipids, phospholipids, carbohydrates, electrolytes, enzymes, nucleic acids, and endogenous metabolites. These constituents may interfere with analytical measurements by causing matrix effects, analyte degradation, ion suppression or enhancement, nonspecific binding, and reduced extraction efficiency. Consequently, careful selection of the biological matrix is a critical determinant of analytical performance and depends on the

pharmacokinetic characteristics of the drug, the objective of the investigation, the required analytical sensitivity, and the intended clinical or regulatory application.

Each biological matrix possesses distinct physicochemical and biochemical characteristics that influence analyte stability, protein binding, extraction efficiency, chromatographic behavior, and detector response. Therefore, the development of robust bioanalytical methods requires a thorough understanding of matrix composition together with appropriate sample preparation techniques and validated analytical procedures to ensure accurate, precise, and reproducible quantification.^{25–42}

2.1 Blood and Plasma

Whole blood and plasma are the most extensively employed biological matrices in pharmaceutical bioanalysis because they directly reflect systemic drug exposure and are essential for pharmacokinetic, bioavailability, bioequivalence, and therapeutic drug monitoring studies. Plasma is obtained by centrifugation of anticoagulated whole blood and contains water, plasma proteins, lipoproteins, electrolytes, hormones, carbohydrates, and numerous endogenous metabolites that may interact with pharmaceutical compounds.

Drug concentrations measured in plasma generally represent systemic exposure and are widely used to characterize pharmacokinetic parameters such as maximum plasma concentration (C_{max}), time to maximum concentration (T_{max}), area under the concentration–time curve (AUC), elimination half-life ($t_{1/2}$), clearance, and volume of distribution. Consequently, plasma remains the preferred biological matrix for regulatory pharmacokinetic investigations and clinical drug development.

Despite its widespread use, plasma presents several analytical challenges due to its complex biochemical composition and high protein content. Extensive protein binding may reduce analyte recovery during extraction, while endogenous phospholipids, lipoproteins, and metabolites can interfere with chromatographic separation and produce ion suppression or ion enhancement in mass spectrometric detection. Matrix effects may compromise analytical accuracy, precision, and sensitivity if appropriate sample preparation strategies are not employed. Therefore, techniques such as protein precipitation (PP), liquid–liquid extraction (LLE), solid-phase extraction (SPE), supported liquid extraction (SLE), and microextraction approaches are routinely used to remove endogenous interferences and improve analyte recovery, chromatographic performance, and quantitative reliability.

2.2 Serum

Serum is another important biological matrix frequently used in clinical diagnostics, therapeutic

drug monitoring, biomarker investigations, and pharmacokinetic studies. It is obtained by allowing whole blood to clot naturally, followed by centrifugation to remove blood cells and clotting components. Unlike plasma, serum does not contain fibrinogen and several coagulation proteins, resulting in a slightly less complex protein composition.

Serum drug concentrations often correlate closely with plasma concentrations and therefore provide valuable information regarding systemic drug exposure and therapeutic efficacy. Owing to standardized collection procedures and widespread clinical acceptance, serum is extensively used for monitoring immunosuppressants, antiepileptic drugs, antibiotics, cardiovascular medications, and other therapeutic agents requiring individualized dosage adjustment.

However, serum analysis is not without limitations. Endogenous proteins, lipids, phospholipids, bilirubin, and metabolic by-products may interfere with chromatographic separation and mass spectrometric detection. In addition, the coagulation process may alter the distribution or stability of certain analytes through adsorption to clot components or enzymatic degradation, potentially affecting measured drug concentrations. Consequently, standardized sample collection, prompt centrifugation, appropriate storage conditions, and validated sample preparation procedures are essential to preserve analyte integrity and ensure accurate quantitative analysis. Careful evaluation of matrix effects, analyte stability, extraction recovery, and method robustness remains critical for obtaining reliable bioanalytical data from serum samples.

2.3 Urine

Urine is one of the most extensively utilized biological matrices for drug analysis because it provides valuable information regarding drug excretion, metabolic pathways, renal clearance, and elimination kinetics. Unlike blood-based matrices, urine collection is non-invasive, painless, and permits repeated sampling without causing significant discomfort to study participants. Furthermore, relatively large sample volumes can be collected, often resulting in higher analyte concentrations than those observed in plasma or serum. Consequently, urine has become the preferred biological matrix for toxicological investigations, forensic drug testing, therapeutic drug monitoring, anti-doping analysis, and assessment of patient compliance.

The composition of urine varies considerably among individuals and is influenced by factors such as hydration status, diet, age, renal function, circadian rhythm, and disease conditions. Variations in pH, ionic strength, specific gravity, and concentrations of endogenous metabolites may significantly influence analyte stability, extraction efficiency, chromatographic behavior, and detector response. In addition, endogenous compounds including urea,

creatinine, salts, amino acids, and metabolic by-products may interfere with analytical measurements or contribute to matrix effects, particularly during mass spectrometric analysis. Therefore, careful optimization of sample preparation procedures, chromatographic separation, and bioanalytical method validation is essential to ensure accurate, precise, and reproducible drug quantification in urine samples.

2.4 Saliva

Saliva has emerged as an attractive, non-invasive biological matrix for quantitative drug analysis owing to its ease of collection, minimal discomfort to patients, and suitability for repeated sampling. Saliva collection does not require trained healthcare personnel, making it particularly advantageous for pediatric, geriatric, forensic, and large-scale clinical studies, as well as home-based therapeutic drug monitoring.

For many therapeutic agents, salivary drug concentrations reflect the pharmacologically active, unbound fraction present in plasma because only free drug molecules can diffuse across the salivary gland epithelium. Consequently, saliva has gained considerable importance in therapeutic drug monitoring, pharmacokinetic investigations, forensic toxicology, and compliance assessment.

Despite these advantages, saliva presents several analytical challenges. Drug concentrations are generally much lower than those found in plasma, necessitating highly sensitive analytical techniques such as LC–MS/MS and UHPLC–MS/MS. In addition, salivary composition is influenced by salivary flow rate, hydration status, circadian rhythm, dietary intake, oral health, pH, and concomitant medications. Enzymatic activity and microbial metabolism within saliva may also contribute to analyte degradation if samples are not processed promptly and stored under appropriate conditions. Consequently, standardized collection procedures, validated sample preparation methods, and rigorous stability assessments are essential to obtain reliable quantitative results.

2.5 Cerebrospinal Fluid (CSF)

Cerebrospinal fluid (CSF) is a specialized biological matrix that surrounds the brain and spinal cord and serves as an important medium for evaluating the penetration of therapeutic agents across the blood–brain barrier (BBB). Quantitative determination of drugs in CSF provides critical information regarding central nervous system (CNS) exposure and is indispensable during the development of drugs intended to treat neurological disorders such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, and central nervous system infections.

Although CSF offers unique pharmacokinetic insights, its routine use is limited by the invasive nature of sample collection, which generally requires lumbar

puncture performed under strict clinical conditions. Sample volumes are often limited, and drug concentrations are typically several orders of magnitude lower than corresponding plasma concentrations, requiring highly sensitive and selective analytical platforms such as LC–MS/MS, UHPLC–MS/MS, and high-resolution mass spectrometry.

Compared with plasma, CSF contains substantially lower concentrations of proteins and lipids, thereby reducing certain matrix effects. Nevertheless, endogenous peptides, neurotransmitters, metabolites, and other biomolecules may still interfere with analytical measurements. Consequently, optimized sample preparation, highly selective chromatographic separation, and comprehensive bioanalytical method validation remain essential for reliable drug quantification in CSF.

2.6 Tissue Samples

Tissue analysis plays a crucial role in evaluating the biodistribution, accumulation, and target-site exposure of pharmaceutical compounds. Quantitative drug determination in tissues is particularly important during preclinical pharmacokinetic investigations, toxicological studies, drug metabolism research, and assessment of tissue-specific therapeutic efficacy. Organs commonly analyzed include the liver, kidney, brain, heart, lung, spleen, adipose tissue, muscle, and tumours, depending on the pharmacological objective.

Unlike biological fluids, tissue samples are highly heterogeneous and structurally complex, comprising cells, extracellular matrix, connective tissue, phospholipids, proteins, nucleic acids, and intracellular organelles. Consequently, tissue analysis generally requires multiple sample preparation steps, including homogenization, protein precipitation, extraction, purification, and concentration prior to chromatographic analysis.

Lipid-rich tissues present additional analytical challenges because lipophilic drugs may partition extensively into cellular membranes, reducing extraction efficiency. Furthermore, endogenous enzymes may continue to metabolize pharmaceutical compounds during sample processing if appropriate stabilization procedures are not implemented. Therefore, optimized tissue handling protocols, validated extraction procedures, and highly sensitive hyphenated analytical techniques are essential to achieve accurate and reproducible quantitative measurements.

Dried blood spot (DBS) sampling has emerged as an innovative microsampling technique that offers a practical alternative to conventional venous blood collection for quantitative drug analysis. In this approach, a small volume of capillary blood, typically obtained by finger prick, is applied onto specialized filter paper and allowed to dry before storage and analysis. DBS sampling has gained widespread acceptance in pharmacokinetic studies, pediatric

research, therapeutic drug monitoring, population pharmacokinetic investigations, and decentralized clinical trials because of its simplicity and minimal invasiveness.

The principal advantages of DBS include reduced blood volume requirements, simplified sample collection, improved patient compliance, enhanced analyte stability, lower transportation costs, and the elimination of cold-chain storage in many applications. These characteristics make DBS particularly valuable for remote sampling, resource-limited settings, neonatal screening, and large multicenter clinical studies.

Dried Blood Spots (DBS) Dried blood spot sampling has emerged as an innovative and minimally invasive technique for drug quantification, particularly in clinical pharmacokinetic studies and remote sample collection. In this method, small volumes of blood are

applied onto specialized filter paper and allowed to dry, creating stable samples that can be easily transported and stored without the need for refrigeration. DBS sampling offers several advantages, including reduced sample volume requirements, simplified collection procedures, and improved sample stability during transportation. However, certain analytical challenges must be addressed when working with DBS samples. Variability in hematocrit levels can influence blood spreading on filter paper, potentially affecting analyte distribution and quantification accuracy. Additionally, the limited sample volume requires highly sensitive analytical techniques to detect drugs present at low concentrations. Careful method validation and calibration strategies are therefore essential to ensure accurate quantification when using DBS-based bioanalytical approaches.

Table 1: Comparative Characteristics and Challenges of Biological Matrices

Biological Matrix	Characteristics	Advantages	Analytical Challenges
Blood / Plasma	Rich in proteins and biomolecules	Reflects systemic drug concentration	Protein binding, matrix effects, phospholipid interference
Serum	Plasma without clotting factors	Commonly used in clinical diagnostics	Protein interference, potential drug degradation
Urine	Contains excreted drugs and metabolites	Non-invasive collection, higher analyte levels	Variable pH, salt interference, metabolic variability
Saliva	Reflects free drug fraction	Non-invasive and convenient sampling	Low drug concentration, enzymatic degradation
CSF	Represents CNS drug exposure	Useful for brain-targeted drugs	Invasive collection, very low analyte levels
Tissue	Indicates drug distribution in organs	Important for toxicology and distribution studies	Complex matrix, extensive sample preparation
DBS	Small blood sample on filter paper	Minimal sample volume, easy storage	Hematocrit effect, limited sensitivity

The selection of a suitable biological matrix is a critical consideration in bioanalytical method development. Each matrix presents unique advantages and analytical challenges that must be carefully addressed through optimized sample preparation techniques, appropriate analytical instrumentation, and rigorous method validation procedures. Understanding these matrix-specific characteristics enables researchers to achieve accurate, reliable, and reproducible quantification of drugs in complex biological environments.

Despite these advantages, DBS analysis presents several analytical challenges. Hematocrit variability influences blood viscosity and spreading

characteristics on filter paper, thereby affecting analyte distribution and quantitative accuracy. Limited sample volume necessitates the use of highly sensitive analytical platforms, most commonly LC–MS/MS, capable of detecting analytes at trace concentrations. Additional factors including punch location, extraction efficiency, blood spot homogeneity, environmental conditions during drying, and long-term storage stability must also be carefully controlled. Consequently, rigorous bioanalytical method validation, standardized sampling procedures, and appropriate calibration strategies are essential to ensure reliable and reproducible drug quantification using DBS-based methodologies.




Figure 1: Workflow of bioanalytical drug determination

(Rakusanova, Stanislava & Cajka, Tomas. (2022). Current analytical methods to monitor type 2 diabetes medication in biological samples. *TrAC Trends in Analytical Chemistry*. 158. 116831. 10.1016/j.trac.2022.116831)

3. Sample Preparation Techniques in Bioanalysis

Sample preparation is a critical component of bioanalytical method development because biological matrices such as plasma, serum, urine, saliva, cerebrospinal fluid, and tissue homogenates contain a wide variety of endogenous substances, including proteins, phospholipids, lipids, carbohydrates, salts, enzymes, and metabolic by-products. These matrix constituents may interfere with analytical measurements by causing analyte degradation, ion suppression or ion enhancement in mass spectrometry, reduced extraction efficiency, and contamination of chromatographic systems. Consequently, appropriate sample preparation is essential to isolate analytes from complex biological matrices while minimizing matrix effects and maximizing analytical performance.

An ideal sample preparation technique should provide high analyte recovery, excellent selectivity, minimal matrix interference, good reproducibility, rapid processing, low solvent consumption, and compatibility with downstream analytical instrumentation. Effective sample preparation not only enhances analytical sensitivity and precision but also prolongs instrument lifetime by reducing contamination of chromatographic columns and mass spectrometric ion sources. Over the past three decades, bioanalytical sample preparation has evolved from conventional extraction techniques to miniaturized, automated, and environmentally sustainable approaches that support high-throughput pharmaceutical analysis.^{43–71}

3.1 Protein Precipitation (PP)

Principle

Protein precipitation (PP) is the simplest and one of the most widely employed sample preparation techniques in quantitative bioanalysis. The technique is based on the denaturation and precipitation of plasma or serum proteins following the addition of organic solvents such as acetonitrile, methanol, or ethanol, or strong acids including perchloric acid and trichloroacetic acid. These reagents reduce protein solubility by disrupting hydrophobic interactions and hydrogen bonding, resulting in protein aggregation and precipitation.

Following precipitation, samples are centrifuged to separate the protein pellet from the analyte-containing supernatant. The supernatant may then be directly injected into chromatographic systems or subjected to evaporation and reconstitution before analysis.

Advantages

- Simple and rapid procedure
- Minimal sample handling
- Low operational cost
- Suitable for high-throughput laboratories
- Compatible with LC–MS/MS and HPLC analyses
- Requires relatively small solvent volumes

Limitations

Despite its simplicity, protein precipitation removes only proteins while many endogenous phospholipids, salts, and metabolites remain in the extract. These residual matrix components may produce ion suppression or enhancement during LC–MS/MS

analysis. Incomplete protein removal, analyte adsorption onto precipitated proteins, and matrix variability may also reduce extraction recovery and quantitative accuracy. Consequently, PP is generally preferred for routine pharmacokinetic studies involving relatively clean analytes but may not be suitable for highly sensitive trace-level bioanalysis.

3.2 Liquid–Liquid Extraction (LLE)

Principle

Liquid–liquid extraction (LLE) is a classical partition-based extraction technique that isolates analytes according to their differential solubility between two immiscible liquid phases, typically an aqueous biological matrix and an organic solvent. Partitioning depends primarily on analyte polarity, pKa, lipophilicity, and solution pH.

After vigorous mixing and phase separation, the organic layer containing the extracted analyte is collected, evaporated under nitrogen or vacuum, and reconstituted in an appropriate solvent before chromatographic analysis.

Common extraction solvents include:

- Ethyl acetate
- Methyl tert-butyl ether (MTBE)
- Dichloromethane
- Diethyl ether
- Hexane

Advantages

- Excellent removal of endogenous matrix components
- High extraction recovery for lipophilic compounds
- Reduced phospholipid interference
- Improved chromatographic performance
- Enhanced analytical sensitivity

Limitations

LLE is relatively labor-intensive and frequently requires large volumes of organic solvents. Emulsion formation may complicate phase separation and reduce extraction efficiency. Furthermore, extraction conditions often require extensive optimization based on analyte physicochemical properties.

3.3 Solid-Phase Extraction (SPE)

Principle

Solid-phase extraction (SPE) is considered the gold standard sample preparation technique for quantitative bioanalysis. In SPE, analytes are selectively retained on a solid sorbent packed inside cartridges, disks, or 96-well plates. Matrix interferences are removed through sequential washing steps before analytes are eluted using appropriate organic solvents.

Common sorbents include:

- C18
- C8

- Phenyl
- Strong cation exchange (SCX)
- Strong anion exchange (SAX)
- Hydrophilic–lipophilic balance (HLB)
- Mixed-mode sorbents

Advantages

- Excellent sample cleanup
- High analyte recovery
- Improved selectivity
- Reduced matrix effects
- Concentration of trace-level analytes
- Excellent compatibility with LC–MS/MS

Limitations

SPE involves multiple processing steps, including cartridge conditioning, equilibration, sample loading, washing, drying, and elution. These procedures increase processing time and operational cost. Optimization of sorbent chemistry and extraction conditions is often necessary for each analyte.

3.4 Solid-Phase Microextraction (SPME)

Principle

Solid-phase microextraction (SPME) is a solvent-free extraction technique that integrates sampling, extraction, concentration, and sample introduction into a single procedure. A fused silica fiber coated with an appropriate sorbent is exposed either directly to the biological sample or to the sample headspace, allowing analytes to partition onto the coating.

After extraction, analytes are thermally desorbed into GC systems or solvent-desorbed for LC analysis.

Advantages

- Solvent-free extraction
- Environmentally friendly
- Minimal sample handling
- High sensitivity for volatile and semi-volatile compounds
- Easily automated
- Compatible with green analytical chemistry principles

Limitations

Limited sorbent capacity, relatively fragile extraction fibers, long equilibrium times for certain analytes, and coating degradation after repeated use may affect reproducibility.

3.5 Microextraction Techniques

Miniaturized extraction approaches have received increasing attention because they substantially reduce solvent consumption while maintaining excellent extraction efficiency and analytical sensitivity.

3.5.1 Dispersive Liquid–Liquid Microextraction (DLLME)

DLLME involves rapid injection of a mixture containing extraction solvent and disperser solvent into an aqueous biological sample, producing a cloudy emulsion composed of fine extraction solvent droplets. The large interfacial surface area facilitates rapid analyte transfer into the extraction solvent. After centrifugation, the enriched extraction phase is collected for chromatographic analysis.

Advantages

- Very high enrichment factors
- Minimal solvent consumption
- Rapid extraction
- Excellent sensitivity

Limitations

- Optimization of extraction solvent is critical
- Less suitable for highly proteinaceous samples without prior cleanup

3.5.2 Hollow-Fiber Liquid-Phase Microextraction (HF-LPME)

HF-LPME utilizes a porous polypropylene hollow fiber impregnated with an organic solvent that functions as a selective membrane between donor and acceptor phases.

The analyte diffuses through the membrane and becomes concentrated inside the acceptor solution.

Advantages

- Excellent selectivity
- Very low solvent consumption
- High enrichment factors
- Suitable for trace-level drug analysis

Limitations

- Longer extraction times
- Careful membrane handling required

3.6 Quenchers

Quenchers (Quick, Easy, Cheap, Effective, Rugged, and Safe) was originally developed for pesticide residue analysis but has gained increasing importance in pharmaceutical bioanalysis.

The procedure generally consists of:

- Extraction with acetonitrile
- Salt-induced phase separation
- Dispersive solid-phase extraction cleanup
- LC–MS/MS analysis

Advantages

- Rapid sample preparation
- Cost-effective
- Low solvent consumption
- Excellent for multiclass analyte extraction
- High-throughput capability

Limitations

Because biological matrices contain substantially higher protein and phospholipid concentrations than food matrices, additional optimization is frequently necessary to minimize matrix effects and improve analyte recovery.

3.7 Automated Sample Preparation

Automation has transformed modern pharmaceutical bioanalysis by improving analytical reproducibility, reducing human error, and increasing laboratory throughput.

Current automated systems include:

- Automated SPE platforms
- Online SPE–LC–MS/MS
- Robotic liquid handlers
- Automated protein precipitation workstations
- Automated microextraction systems
- 96- and 384-well plate extraction platforms

These technologies are capable of processing hundreds to thousands of samples per day, making them particularly valuable for pharmacokinetic, bioequivalence, toxicokinetic, and clinical studies.

Advantages

- High throughput
- Excellent reproducibility
- Reduced analyst variability
- Lower contamination risk
- Reduced labor costs
- Improved regulatory compliance

Limitations

The principal limitation of automated sample preparation is the high capital investment required for instrumentation and laboratory infrastructure. Additional challenges include software validation, routine maintenance, operator training, and method transfer between automated platforms.

Future Trends in Sample Preparation

Recent advances are driving the development of next-generation sample preparation technologies that emphasize miniaturization, automation, sustainability, and integration with advanced analytical instrumentation. Emerging approaches include magnetic solid-phase extraction, fabric phase sorptive extraction, thin-film microextraction, molecularly imprinted polymers, microfluidic sample preparation devices, paper-based analytical platforms, and fully integrated online extraction systems. These innovations are expected to reduce sample preparation time, minimize solvent consumption, improve extraction efficiency, and facilitate high-throughput bioanalysis in pharmaceutical research, clinical pharmacology, and precision medicine.

4. Chromatographic Bioanalytical Techniques

Chromatographic techniques constitute the foundation of modern bioanalysis and remain the most widely employed analytical approaches for the qualitative and quantitative determination of drugs, metabolites, and biomarkers in biological matrices. These techniques separate analytes based on their differential distribution between a stationary phase and a mobile phase, allowing compounds with similar physicochemical properties to be resolved efficiently. The separation process depends on multiple factors, including molecular polarity, hydrophobicity, ionic interactions, molecular size, and affinity toward the stationary phase.

The remarkable versatility, sensitivity, selectivity, and reproducibility of chromatographic techniques have made them indispensable in pharmaceutical research, clinical pharmacology, therapeutic drug monitoring (TDM), pharmacokinetic (PK) and pharmacodynamic (PD) studies, bioavailability and bioequivalence investigations, toxicology, metabolomics, and forensic analysis. Continuous technological advancements in chromatographic instrumentation, stationary-phase chemistry, and detector technology have substantially improved analytical performance, enabling rapid and highly sensitive quantification of drugs in complex biological matrices.^{72–88}

4.1 High-Performance Liquid Chromatography (HPLC)

Principle

High-performance liquid chromatography (HPLC) is one of the most established and extensively utilized analytical techniques in pharmaceutical and bioanalytical sciences. In HPLC, the sample is introduced into a liquid mobile phase that is pumped through a chromatographic column packed with a stationary phase under high pressure. As analytes migrate through the column, differences in their interactions with the stationary phase result in efficient chromatographic separation.

Reverse-phase HPLC (RP-HPLC), employing hydrophobic stationary phases such as C18 or C8 columns, is the most commonly used mode for pharmaceutical bioanalysis because of its broad applicability to drugs with varying physicochemical properties.

Detection Systems

HPLC is compatible with a wide range of detectors, including:

- Ultraviolet (UV) detector
- Photodiode array (PDA/DAD) detector
- Fluorescence detector (FLD)
- Electrochemical detector (ECD)
- Evaporative light-scattering detector (ELSD)
- Refractive index detector (RID)
- Mass spectrometric detector (LC–MS)

Applications

HPLC has been extensively employed for:

- Quantification of drugs and metabolites
- Pharmacokinetic studies
- Therapeutic drug monitoring
- Bioavailability and bioequivalence studies
- Stability studies
- Impurity profiling
- Clinical and forensic toxicology

Advantages

- Excellent precision and reproducibility
- Wide applicability
- Robust analytical performance
- Compatibility with multiple detectors
- Suitable for routine quality control

Limitations

Although HPLC remains one of the most versatile chromatographic techniques, conventional systems generally require longer analysis times, higher mobile-phase consumption, and lower analytical throughput compared with modern ultra-high-performance chromatographic systems.

4.2 Ultra-High-Performance Liquid Chromatography (UHPLC/UPLC)

Principle

Ultra-high-performance liquid chromatography (UHPLC), also referred to as ultra-performance liquid chromatography (UPLC), represents a significant advancement over conventional HPLC. UHPLC utilizes columns packed with sub-2 μm particles operated at pressures that may exceed 15,000 psi, resulting in substantially improved chromatographic efficiency.

Smaller particle sizes increase column efficiency, reduce peak dispersion, improve mass-transfer kinetics, and produce narrower chromatographic peaks with enhanced sensitivity.

Applications

UHPLC has become the preferred chromatographic platform for:

- High-throughput pharmacokinetic studies
- Clinical bioanalysis
- Therapeutic drug monitoring
- Impurity profiling
- Metabolomics
- Pharmaceutical quality control

UHPLC is particularly valuable when coupled with tandem mass spectrometry (UHPLC–MS/MS), providing exceptional sensitivity and rapid quantitative analysis.

Advantages

- Higher chromatographic resolution
- Shorter analytical run times

- Lower solvent consumption
- Increased sensitivity
- Higher sample throughput
- Improved chromatographic efficiency

Limitations

The principal limitations of UHPLC include the higher capital cost of instrumentation, increased maintenance requirements, and the need for specialized columns capable of withstanding ultrahigh operating pressures.

4.3 Gas Chromatography (GC)

Principle

Gas chromatography (GC) is a highly efficient separation technique primarily designed for volatile and thermally stable compounds. In GC, analytes are vaporized and transported through a capillary column by an inert carrier gas such as helium, hydrogen, or nitrogen. Separation occurs according to differences in analyte volatility and interactions with the stationary phase.

For nonvolatile pharmaceuticals, chemical derivatization is frequently required to improve volatility and thermal stability before analysis.

Detection Systems

GC is commonly coupled with:

- Flame ionization detector (FID)
- Electron capture detector (ECD)
- Nitrogen-phosphorus detector (NPD)
- Mass spectrometry (GC–MS)
- Tandem mass spectrometry (GC–MS/MS)

Applications

GC is extensively employed for:

- Drugs of abuse
- Toxicological screening
- Volatile metabolites
- Residual solvent analysis
- Environmental contaminants
- Clinical forensic investigations

Advantages

- Excellent chromatographic resolution
- High sensitivity
- Outstanding reproducibility
- Fast analysis
- Excellent compatibility with mass spectrometry

Limitations

GC is unsuitable for many polar, thermolabile, or high-molecular-weight pharmaceuticals without prior derivatization, increasing analytical complexity and sample preparation time.

4.4 High-Performance Thin-Layer Chromatography (HPTLC)

Principle

High-performance thin-layer chromatography (HPTLC) is an advanced planar chromatographic technique that utilizes precoated plates with finely divided stationary phases to achieve improved separation compared with conventional TLC.

Samples are applied as narrow bands, and separation occurs through capillary migration of the mobile phase. Detection is performed using densitometric scanning under ultraviolet, visible, or fluorescence conditions.

Applications

HPTLC is commonly used for:

- Herbal drug standardization
- Pharmaceutical screening
- Stability studies
- Impurity analysis
- Simultaneous multicomponent analysis

Advantages

- Simultaneous analysis of multiple samples
- Low operational cost
- Reduced solvent consumption
- Simple instrumentation
- Suitable for routine screening

Limitations

Compared with HPLC and LC–MS/MS, HPTLC generally provides lower sensitivity, lower quantitative accuracy, and reduced suitability for trace-level drug analysis in biological matrices.

4.5 Capillary Electrophoresis (CE)

Principle

Capillary electrophoresis (CE) separates analytes according to differences in electrophoretic mobility within narrow fused-silica capillaries under the influence of a high-voltage electric field. Migration depends primarily on the charge-to-size ratio of analytes and electroosmotic flow.

Several operational modes have been developed, including:

- Capillary zone electrophoresis (CZE)
- Micellar electrokinetic chromatography (MEKC)
- Capillary gel electrophoresis (CGE)
- Capillary isotachopheresis (CITP)
- Capillary electrochromatography (CEC)

Applications

CE is particularly useful for:

- Peptide analysis

- Protein characterization
- Chiral separations
- Nucleic acid analysis
- Polar pharmaceutical compounds
- Biomarker analysis

- Excellent suitability for ionic compounds

Advantages

- Extremely high separation efficiency
- Very low sample volume requirements
- Minimal reagent consumption
- Rapid analysis
- Environmentally friendly

Limitations

The primary limitation of conventional CE is relatively poor concentration sensitivity compared with LC–MS/MS. Consequently, on-capillary preconcentration techniques and hyphenation with mass spectrometry (CE–MS) are increasingly employed to improve analytical performance for trace-level bioanalysis.

Table 3.Comparative Evaluation of Chromatographic Techniques

Technique	Separation Efficiency	Sensitivity	Analysis Time	Solvent Consumption	Typical Bioanalytical Applications
HPLC	High	High	Moderate	Moderate	Pharmacokinetics, TDM, routine analysis
UHPLC	Very High	Very High	Short	Low	High-throughput bioanalysis, LC–MS/MS
GC	Very High	High	Short	Very Low	Volatile compounds, toxicology, forensic analysis
HPTLC	Moderate	Moderate	Moderate	Low	Screening, herbal analysis, quality control
CE	Very High	Moderate	Short	Very Low	Polar compounds, peptides, biomolecules

Future Perspectives

Recent advances in chromatographic bioanalysis emphasize greater analytical speed, improved sensitivity, reduced environmental impact, and seamless integration with advanced detection systems. Emerging developments include multidimensional chromatography, microflow and nanoflow liquid chromatography, supercritical fluid chromatography (SFC), chip-based chromatographic systems, automated online sample preparation, and artificial intelligence-assisted chromatographic optimization. Among these innovations, **UHPLC–MS/MS, LC–HRMS, and multidimensional chromatographic platforms** are expected to remain the principal technologies for next-generation quantitative

bioanalysis because of their ability to provide exceptional sensitivity, selectivity, and high-throughput analysis for complex biological samples.

The use of point-of-care devices for drug monitoring offers several advantages, including rapid turnaround time, minimal sample requirements, and improved patient accessibility. These systems are especially valuable in emergency medicine, remote healthcare settings, and personalized medicine applications. However, achieving the same level of analytical sensitivity and accuracy as laboratory-based methods remains a significant challenge. Ongoing research is focused on improving sensor performance, integrating advanced detection technologies, and enhancing device reliability.

Table 4:Eemerging bioanalytical technologies

Technology	Key Principle	Advantages	Limitations	Potential Applications
Microfluidic Bioanalysis	Manipulation of small fluid volumes in microchannels	Reduced sample consumption, rapid analysis	Fabrication complexity	Drug screening, pharmacokinetic studies
Lab-on-a-Chip	Integration of multiple analytical processes on a microchip	Miniaturization, automation	High development cost	Clinical diagnostics
Biosensors and Nanobiosensors	Biological recognition with signal transduction	High selectivity and rapid detection	Stability of biological components	Therapeutic drug monitoring
Nanotechnology Detection Systems	Use of nanoparticles for signal enhancement	Extremely high sensitivity	Nanomaterial reproducibility	Trace-level drug detection

Artificial Intelligence	Data analysis and predictive modeling	Automation and improved accuracy	Requires large datasets	Method optimization
Point-of-Care Devices	Portable analytical systems for immediate testing	Rapid and convenient analysis	Limited sensitivity compared to lab methods	Clinical monitoring

Emerging bioanalytical technologies are reshaping the future of pharmaceutical analysis by enabling faster, more sensitive, and more portable analytical platforms. The integration of microfluidics, nanotechnology, biosensing, and artificial intelligence is expected to significantly improve the efficiency of drug detection and monitoring in biological systems. These technologies hold considerable promise for advancing personalized medicine, improving clinical diagnostics, and supporting next-generation bioanalytical research.

BIOANALYTICAL METHOD VALIDATION¹⁰³⁻¹¹⁹

Bioanalytical method validation is a critical process that ensures the reliability, accuracy, and reproducibility of analytical methods used for the quantitative determination of drugs and their metabolites in biological matrices. Since bioanalytical data are frequently used to support regulatory submissions, pharmacokinetic evaluations, and clinical studies, validated analytical methods must comply with internationally accepted regulatory standards. Method validation establishes that an analytical procedure is suitable for its intended purpose and consistently produces accurate and precise results. Regulatory authorities such as the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) have developed comprehensive guidelines outlining the parameters and acceptance criteria for bioanalytical method validation. These guidelines ensure uniformity and reliability in analytical practices across pharmaceutical research and development.

Accuracy

Accuracy refers to the closeness of the measured concentration of an analyte to its true or nominal value. In bioanalytical method validation, accuracy is typically assessed by analyzing quality control samples containing known concentrations of the analyte at multiple levels, such as low, medium, and high concentrations within the calibration range. The results are compared with the theoretical values to determine the degree of deviation. Accurate analytical methods are essential for reliable interpretation of pharmacokinetic and clinical study data. Regulatory

guidelines generally specify that the mean concentration should fall within an acceptable percentage deviation from the nominal value, ensuring that the analytical method produces results that reflect the actual analyte concentration present in the biological sample.

Precision

Precision describes the degree of agreement between repeated measurements obtained from multiple analyses of the same sample under identical conditions. It reflects the reproducibility of the analytical method and is usually expressed as the relative standard deviation or coefficient of variation of replicate measurements. Precision is commonly evaluated at two levels: intra-day precision, which measures repeatability within the same analytical run, and inter-day precision, which assesses reproducibility across different days or analytical batches. High precision indicates that the method produces consistent results and minimizes analytical variability, which is crucial for reliable drug concentration measurements during pharmacokinetic and clinical studies.

Selectivity

Selectivity refers to the ability of an analytical method to accurately measure the analyte of interest in the presence of other components within the biological matrix. Biological fluids such as plasma or serum contain numerous endogenous compounds, including proteins, lipids, and metabolites, which may interfere with analytical detection. A selective method can effectively distinguish the analyte signal from these interfering substances. During validation, selectivity is evaluated by analyzing blank samples from multiple biological sources to confirm that no significant interference occurs at the retention time or detection wavelength of the analyte. High selectivity ensures accurate quantification even in complex biological environments.

Linearity

Linearity represents the ability of an analytical method to produce results that are directly proportional to the concentration of the analyte within a specified range. In bioanalytical validation, calibration curves are constructed by analyzing standard solutions containing

known concentrations of the analyte across a defined concentration range. The relationship between analyte concentration and detector response is then evaluated using statistical regression analysis. A method demonstrating good linearity allows accurate quantification of unknown samples within the established calibration range, which is essential for reliable pharmacokinetic data interpretation.

Limit of Detection (LOD) and Limit of Quantification (LOQ)

The limit of detection and limit of quantification are important parameters that define the sensitivity of an analytical method. The limit of detection represents the lowest concentration of an analyte that can be reliably detected but not necessarily quantified with acceptable precision and accuracy. In contrast, the limit of quantification represents the lowest concentration that can be quantitatively determined with acceptable accuracy and precision. These parameters are particularly important when analyzing drugs present at very low concentrations in biological matrices. Highly sensitive analytical techniques such as liquid chromatography coupled with mass spectrometry are often required to achieve sufficiently low detection and quantification limits.

Matrix Effect

Matrix effects occur when endogenous components present in biological samples influence the analytical response of the analyte during detection. These effects are especially relevant in mass spectrometric techniques, where co-eluting matrix components can suppress or enhance ionization efficiency, leading to inaccurate quantification. Evaluation of matrix effects typically involves comparing the analytical response of analytes in extracted biological samples with that of analytes prepared in pure solvent. Minimizing matrix effects through appropriate sample preparation and optimized chromatographic conditions is essential to ensure reliable analytical performance.

Stability Studies

Stability studies are conducted to determine whether the analyte remains chemically stable during sample collection, storage, processing, and analysis. Biological samples may undergo degradation due to enzymatic activity, temperature fluctuations, or exposure to light. Stability assessments typically include various experimental conditions such as short-term stability at room temperature, long-term stability during storage, freeze-thaw stability, and post-preparative stability within the analytical system. Demonstrating analyte stability under these conditions

ensures that the measured drug concentration accurately reflects the original sample composition.

Regulatory Guidelines for Bioanalytical Validation

International regulatory agencies have established detailed guidelines to standardize bioanalytical method validation procedures. The US FDA bioanalytical method validation guideline provides comprehensive recommendations regarding method development, validation parameters, sample analysis, and documentation requirements. These guidelines emphasize the importance of accuracy, precision, selectivity, sensitivity, and reproducibility in bioanalytical methods used for regulatory submissions. Similarly, the European Medicines Agency (EMA) has issued guidelines for bioanalytical method validation that align closely with FDA recommendations but also include additional considerations for ligand-binding assays and biological drug analysis. The EMA guidelines emphasize the need for thorough validation to ensure data reliability in pharmacokinetic and bioequivalence studies.

The International Council for Harmonisation (ICH) provides globally accepted guidelines that support harmonization of pharmaceutical analytical practices. Although ICH guidelines focus primarily on analytical method validation for pharmaceutical products, their principles are widely applied in bioanalytical validation to ensure consistency in analytical quality standards across different regulatory regions.

APPLICATIONS IN DRUG DEVELOPMENT¹²⁰⁻¹⁴⁶

Bioanalytical techniques play a central role in pharmaceutical drug development by enabling accurate measurement of drugs and their metabolites in biological systems. Reliable quantification of drug concentrations provides essential information regarding the pharmacological behavior, safety, and efficacy of therapeutic agents. Throughout the drug development process, bioanalytical methods are applied in a variety of studies that support regulatory approval and clinical application. These studies include pharmacokinetic evaluations, bioavailability assessments, therapeutic drug monitoring, toxicological investigations, and clinical trials.

Pharmacokinetic Studies

Pharmacokinetic studies investigate the time-dependent movement of drugs within the body, including processes such as absorption, distribution, metabolism, and excretion. Accurate measurement of drug concentrations in biological fluids is essential for determining pharmacokinetic parameters such as maximum plasma concentration, time to reach

maximum concentration, elimination half-life, and area under the concentration–time curve. Bioanalytical techniques such as liquid chromatography coupled with mass spectrometry are widely employed to quantify drugs in plasma or serum samples collected during pharmacokinetic studies. These data provide valuable insights into drug behavior and help establish appropriate dosing regimens.

Bioavailability and Bioequivalence Studies

Bioavailability studies evaluate the rate and extent to which a drug reaches systemic circulation after administration. These studies are particularly important when assessing new formulations or drug delivery systems. Bioequivalence studies, on the other hand, compare the pharmacokinetic profiles of two pharmaceutical products, typically a generic formulation and a reference product, to demonstrate that they provide comparable therapeutic effects. Accurate bioanalytical measurement of drug concentrations in biological samples is essential for determining pharmacokinetic parameters used in bioequivalence assessments. Regulatory authorities rely on these studies to ensure that generic drugs meet the same safety and efficacy standards as their reference counterparts.

Therapeutic Drug Monitoring

Therapeutic drug monitoring involves the measurement of drug concentrations in biological fluids to ensure that they remain within the therapeutic range required for optimal clinical efficacy. This approach is particularly important for drugs with narrow therapeutic indices, where small variations in concentration may lead to reduced efficacy or increased toxicity. Bioanalytical methods enable clinicians to monitor drug levels in plasma or serum and adjust dosing regimens accordingly. Therapeutic drug monitoring is commonly applied to drugs used in the treatment of epilepsy, cardiovascular disorders, infections, and organ transplantation.

Toxicokinetic Studies

Toxicokinetic studies focus on understanding the relationship between drug exposure and potential toxic effects within the body. These studies are typically conducted during preclinical drug development using animal models to evaluate the safety profile of new drug candidates. Bioanalytical techniques are used to quantify drug concentrations in biological fluids and tissues, allowing researchers to correlate systemic exposure with observed toxicological outcomes. The resulting data help establish safe dosage limits and identify potential risks associated with long-term drug administration.

Clinical Trials

Clinical trials represent a critical stage in drug development where the safety and efficacy of a pharmaceutical product are evaluated in human subjects. Bioanalytical methods play an essential role in clinical trials by providing accurate measurement of drug concentrations in biological samples collected from study participants. These measurements support pharmacokinetic analysis, dose optimization, and evaluation of drug–drug interactions. Reliable bioanalytical data are also required to ensure regulatory compliance and support the approval of new therapeutic agents.

Metabolite Identification

During drug metabolism, pharmaceutical compounds may undergo enzymatic transformation to form metabolites that can possess pharmacological activity or toxicity. Identification and quantification of these metabolites are important aspects of drug development and safety assessment. Advanced analytical techniques such as liquid chromatography–mass spectrometry and high-resolution mass spectrometry are commonly used to detect and characterize drug metabolites in biological matrices. Metabolite identification studies help researchers understand metabolic pathways, evaluate potential drug interactions, and assess the overall safety profile of therapeutic agents.

COMPARATIVE ANALYSIS OF BIOANALYTICAL TECHNIQUES¹⁴⁷⁻¹⁸²

The selection of an appropriate bioanalytical technique is a critical aspect of pharmaceutical analysis, particularly for the accurate quantification of drugs in biological matrices. Various analytical methods differ significantly in terms of sensitivity, selectivity, operational complexity, cost, and analytical time. Consequently, the choice of technique depends on several factors including the physicochemical properties of the analyte, required detection limits, sample matrix complexity, and the purpose of the analysis. Modern bioanalysis often relies on highly sensitive and selective analytical platforms such as liquid chromatography coupled with mass spectrometry, whereas conventional methods such as spectrophotometry or thin layer chromatography may still be used for preliminary or routine analysis where ultra-trace detection is not required.

Chromatographic techniques generally offer superior separation capability and are widely applied for complex biological matrices. Among them, liquid chromatography–mass spectrometry has emerged as the gold standard for drug quantification due to its exceptional sensitivity and selectivity. Similarly, ultra-

performance liquid chromatography provides faster analysis with improved resolution compared to traditional high-performance liquid chromatography. Gas chromatography is particularly useful for volatile or semi-volatile compounds, while high-performance thin layer chromatography offers a cost-effective alternative for screening multiple samples simultaneously. Capillary electrophoresis, on the other hand, provides high separation efficiency for ionic compounds with minimal solvent consumption. Spectroscopic techniques such as ultraviolet-visible spectrophotometry and fluorescence spectroscopy are comparatively simple and economical but may suffer

from limited selectivity when analyzing complex biological matrices. These techniques are often employed for preliminary studies or routine quality control rather than trace-level bioanalysis. In contrast, hyphenated analytical techniques that combine chromatographic separation with advanced detection systems have significantly enhanced the reliability and sensitivity of modern bioanalytical analysis. A comparative evaluation of commonly used bioanalytical techniques is presented in the following table, highlighting their analytical performance characteristics and typical applications.

Table 5: Major Bioanalytical Techniques

Technique	Sensitivity	Selectivity	Cost	Analysis Time	Typical Applications
UV–Visible Spectrophotometry	Low to moderate	Low	Low	Very fast	Preliminary drug analysis, routine quality control
Fluorescence Spectroscopy	Moderate to high	Moderate	Moderate	Fast	Analysis of fluorescent drugs and metabolites
High-Performance Liquid Chromatography (HPLC)	High	High	Moderate	Moderate	Quantification of drugs in plasma and serum
Ultra Performance Liquid Chromatography (UPLC)	Very high	High	High	Very fast	High-throughput pharmaceutical bioanalysis
Gas Chromatography (GC)	High	High	Moderate to high	Moderate	Volatile drug and metabolite analysis
LC–MS/MS	Extremely high	Very high	Very high	Moderate	Pharmacokinetic studies, therapeutic drug monitoring
High Performance Thin Layer Chromatography (HPTLC)	Moderate	Moderate	Low	Fast	Screening and qualitative analysis
Capillary Electrophoresis (CE)	Moderate	High	Moderate	Fast	Analysis of ionic or polar compounds
Biosensor-Based Techniques	High	Very high	Moderate	Very fast	Rapid drug monitoring and clinical diagnostics
Microfluidic Analytical Systems	High	High	Moderate to high	Very fast	Miniaturized drug analysis and point-of-care testing

From the comparative assessment, it is evident that hyphenated techniques such as LC–MS/MS and UPLC–MS provide the highest sensitivity and selectivity for trace-level drug detection in biological samples. These techniques are therefore extensively used in pharmacokinetic studies, clinical research, and regulatory submissions. However, the high cost and sophisticated instrumentation associated with these methods may limit their accessibility in certain laboratories. Conversely, conventional techniques remain valuable for routine analysis due to their simplicity and cost-effectiveness.

Overall, the comparative evaluation of bioanalytical techniques highlights the importance of selecting an appropriate analytical approach based on the specific requirements of the study. Advances in analytical instrumentation continue to improve sensitivity, reduce analysis time, and expand the capabilities of bioanalytical research, thereby supporting more efficient and reliable drug development processes.

CONCLUSION

Bioanalytical techniques are indispensable for the accurate quantification of drugs and their metabolites in biological matrices during pharmaceutical research

and clinical studies. Advanced analytical technologies such as HPLC, UPLC, and LC–MS/MS have significantly enhanced the sensitivity, selectivity, and reliability of drug analysis. Appropriate sample preparation methods and adherence to regulatory validation guidelines further ensure analytical accuracy and reproducibility. Emerging technologies including microfluidics, biosensors, and nanotechnology are expected to improve analytical efficiency and enable rapid diagnostic applications. Continued advancements in bioanalytical methodologies will support drug discovery, pharmacokinetic evaluation, and personalized therapeutic monitoring in the future.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The authors declare that they have no conflict of interest.

Author Contributions

All authors contributed to the conception, literature review, manuscript preparation, critical revision, and final approval of the manuscript. All authors have read and approved the final version.

Ethical Approval

Ethical approval was not required for this study because it is a review article based exclusively on published literature.

Data Availability Statement

No new datasets were generated or analyzed during the current study. All information included in this review was obtained from previously published literature.

Acknowledgements

The authors sincerely thank their respective institutions for providing the necessary facilities and support for the preparation of this review manuscript.

Abbreviations

- ADME – Absorption, Distribution, Metabolism and Excretion
- AI – Artificial Intelligence
- CE – Capillary Electrophoresis
- CNS – Central Nervous System
- CSF – Cerebrospinal Fluid
- DBS – Dried Blood Spot
- DLLME – Dispersive Liquid–Liquid Microextraction
- EMA – European Medicines Agency
- GC – Gas Chromatography
- HPLC – High-Performance Liquid Chromatography

- HPTLC – High-Performance Thin-Layer Chromatography
- HRMS – High-Resolution Mass Spectrometry
- LC–MS – Liquid Chromatography–Mass Spectrometry
- LC–MS/MS – Liquid Chromatography–Tandem Mass Spectrometry
- LLE – Liquid–Liquid Extraction
- LOD – Limit of Detection
- LOQ – Limit of Quantification
- PK – Pharmacokinetics
- PD – Pharmacodynamics
- PP – Protein Precipitation
- QC – Quality Control
- QuEChERS – Quick, Easy, Cheap, Effective, Rugged and Safe
- RID – Refractive Index Detector
- RP-HPLC – Reverse-Phase High-Performance Liquid Chromatography
- SPE – Solid-Phase Extraction
- SPME – Solid-Phase Microextraction
- TDM – Therapeutic Drug Monitoring
- UHPLC/UPLC – Ultra-High-Performance Liquid Chromatography
- US FDA – United States Food and Drug Administration
- UV – Ultraviolet

REFERENCES

1. Alanazi S. Recent advances in liquid chromatography–mass spectrometry applications in biological sciences. *Anal Chim Acta*. 2025;1281:342105.
2. Khan RMN, Patel S, Singh V. Recent advances in bioanalytical methodologies for pharmaceutical analysis. *Bioanalysis*. 2025;17(2):115-134.
3. Panda SS, Sharma A. Bioanalysis of anticancer agents using LC–MS techniques. *Trends Anal Chem*. 2023;159:116902.
4. Malarvannan M, Patel R. Advances in analytical technologies for emerging drug modalities. *Anal Chim Acta*. 2024;1234:340812.
5. Stamou P, Smith J. Hydrophilic interaction LC-MS techniques in pharmaceutical bioanalysis. *J Chromatogr B*. 2023;1208:123380.
6. Zhou Z, Li X. Advances in sample preparation techniques for pharmaceutical bioanalysis. *Talanta*. 2024;254:124118.
7. Zhang Y, Wang L. Recent developments in microextraction techniques for drug analysis in biological samples. *Anal Chim Acta*. 2024;1255:341205.
8. Li D, He Q. Nanomaterial-based biosensors for drug monitoring in biological fluids. *Biosens Bioelectron*. 2023;229:115247.

9. Chen G, Pramanik BN. Advances in LC–MS bioanalysis for pharmaceutical drug development. *Bioanalysis*. 2024;16(3):165-182.
10. Xu RN, Fan L. High-throughput LC–MS/MS bioanalysis in pharmacokinetic studies. *J Pharm Biomed Anal*. 2024;226:115240.
11. Patel P, Sharma P. Biosensor technologies for therapeutic drug monitoring. *Talanta*. 2023;249:123728.
12. Liu Y, Zhao W. Nanotechnology-based analytical platforms for pharmaceutical bioanalysis. *Anal Chim Acta*. 2023;1246:340548.
13. Huang M, Zhou Q. Artificial intelligence applications in analytical chemistry. *Anal Chim Acta*. 2024;1252:341026.
14. Li J, Chen X. Microfluidic devices for rapid bioanalytical drug determination. *Talanta*. 2023;247:123548.
15. Wang L, Zhao X. Nanoparticle-assisted detection systems for trace drug analysis. *Biosens Bioelectron*. 2024;232:115362.
16. Singh A, Mehta P. Bioanalytical methods in therapeutic drug monitoring. *Bioanalysis*. 2023;15(12):897-910.
17. Zhou Y, Chen H. Application of QuEChERS extraction in pharmaceutical bioanalysis. *Talanta*. 2024;255:124322.
18. Bhandari S, Bhandari A. Advances in chromatographic techniques for pharmaceutical bioanalysis. *J Pharm Biomed Anal*. 2024;229:115328.
19. Patel M, Shah R. UPLC–MS/MS techniques for ultra-trace drug analysis. *J Chromatogr B*. 2023;1205:123349.
20. Zhang H, Li P. Capillary electrophoresis in pharmaceutical bioanalysis. *J Chromatogr B*. 2023;1213:123421.
21. Pragst F, Herzler M, Erxleben BT. Systematic toxicological analysis by high-performance liquid chromatography with diode array detection (HPLC-DAD). *Clin Chem Lab Med*. 2004;42:1325-1340.
22. Kratzsch C, Tenberken O, Peters FT, Weber AA, Kraemer T, Maurer HH. Screening library-assisted identification and validated quantification of benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography–mass spectrometry. *J Mass Spectrom*. 2004;39:856-872.
23. Rivera HM, Walker GS, Sims DN, Stockham PC. Application of liquid chromatography-tandem mass spectrometry to the analysis of benzodiazepines in blood. *Eur J Mass Spectrom*. 2003;9:599-607.
24. Højskov CS, Heickendorff L, Møller HJ. High-throughput liquid–liquid extraction and LC-MS/MS assay for determination of circulating 25-hydroxy vitamin D3 and D2 in clinical laboratory samples. *Anal Chim Acta*. 2010;411:114-116.
25. Goeringer KE, Raymon L, Christian GD, Logan BK. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: pharmacology and report of 168 cases. *J Forensic Sci*. 2000;45:633-648.
26. Shewiyo DH, Kaale E, Risha PG, Dejaegher B, Verbeke JS, Van Heyden Y. HPTLC methods to assay active ingredients in pharmaceutical formulations: review of method development and validation steps. *J Pharm Biomed Anal*. 2012;66:11-23.
27. Debebe Z, Nekhai S, Ashenafi M, Lovejoy DB, Kalinowski DS, Gordeuk VR, et al. Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2012;906:25-32.
28. Mastovska K, Hajslova J, Godula M, Krivankova J, Kocourek V. Fast temperature programming in routine analysis of multiple pesticide residues in food matrices. *J Chromatogr A*. 2001;907:235-245.
29. Sood S, Bala R, Gill NS. Method development and validation using HPLC technique: a review. *J Drug Discov Ther*. 2014;2:18-24.
30. Singh PK, Pande M, Singh LK, Tripathi RB. Steps to be considered during method development and validation for analysis of residual solvents by gas chromatography. *Int Res J Pharm Appl Sci*. 2013;3:74-80.
31. Charde MS, Welankiwar AS, Kumar J. Method development by liquid chromatography with validation. *Int J Pharm Chem*. 2014;4:57-61.
32. Chinchole R, Mahatre P, Desai U, Chavan R. Recent applications of hyphenated liquid chromatography techniques. *Int J Pharm Sci Rev Res*. 2012;14:57-63.
33. Karuwan C, Wisitsoraat A, Maturos T, Phokharatkul D, Sappat A, Jaruwongrungeesee K, et al. Flow injection based microfluidic device with carbon nanotube electrode for rapid salbutamol detection. *Talanta*. 2009;79:995-1000.
34. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol*. 2008;14:4300-4308.
35. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular

- carcinogenesis. *Gastroenterology*. 2007;132:2557-2576.
36. Worns MA, Galle PR. Future perspectives in hepatocellular carcinoma. *Dig Liver Dis*. 2010;42(Suppl 3):S302-S309.
 37. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. *Cancer*. 2000;89:500-507.
 38. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. Management of hepatocellular carcinoma: expert opinion and recommendations from the World Congress on Gastrointestinal Cancer. *Ann Oncol*. 2009;20(Suppl 7):vii1-vii6.
 39. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. *J Hepatol*. 2011;54:705-715.
 40. Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. *Intervirol*. 2008;51(Suppl 1):34-41.
 41. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. *Cancer Res*. 2001;61:3225-3229.
 42. Rudrapal M, Hussain M. Method development and validation of gemifloxacin in tablet dosage form by RP-HPLC. *J Drug Deliv Ther*. 2020;10(4):97-101.
 43. Gage GP, Rudrapal M, Jadhav AG, Bendale AR, Borse LB. Development and validation of RP-HPLC method for estimation of pidotimod in tablet dosage form. *Int J Pharm Res*. 2020;12(4):30-35.
 44. International Organization for Standardization. ISO Guide 8402: Quality vocabulary. Geneva: ISO; 1994.
 45. Surya Kiran BVVS, Sridhar N, Raghavendra M, Rudrapal M. Development and validation of RP-HPLC method for simultaneous estimation of minoxidil and aminexil in topical formulation. *Asian J Chem*. 2016;28(1):157-160.
 46. Rudrapal M, Oduri MU, Samidala NR, Surya Kiran BVVS, Junejo JA, Singh KD, et al. Development and validation of RP-HPLC method for simultaneous estimation of olmesartan and hydrochlorothiazide in tablet dosage form. *Orient J Chem*. 2015;31(2):921-926.
 47. Ahuja S, Dong MW. Handbook of pharmaceutical analysis by HPLC. Vol. 6. Elsevier; 2005. p. 60-76.
 48. Wong SHY. Advances in liquid chromatography and related methodologies for therapeutic drug monitoring. *J Pharm Biomed Anal*. 1989;7:1011-1032.
 49. Fang J, Baker GB, Coutts RT. Determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron capture detection. *J Chromatogr B Biomed Appl*. 1996;682:283-288.
 50. Cerretani D, Micheli L, Fiaschi AI, Giorgi G. Rapid determination of piroxicam in rat plasma, muscle and skin by HPLC. *J Chromatogr B Biomed Appl*. 1993;614:103-108.
 51. Hsien JYK, Lin C, Matuszewski BK, Dobrinska MR. Automated determination of hydrochlorothiazide in human plasma and urine. *J Pharm Biomed Anal*. 1994;12:1555-1562.
 52. Cara P. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in LC-MS/MS. *J Chromatogr B*. 2003;785:263-275.
 53. Rakusanova, Stanislava & Cajka, Tomas. (2022). Current analytical methods to monitor type 2 diabetes medication in biological samples. *TrAC Trends in Analytical Chemistry*. 158. 116831. 10.1016/j.trac.2022.116831
 54. Egbuna C, Ifemeje JC, Udedi SC, Kumar S, editors. *Phytochemistry. Vol. 1: Fundamentals, methods and applications*. New York: Apple Academic Press/CRC Press; 2018. p. 684.
 55. Egbuna C, Ifemeje JC, Maduako MC, Tijjani H, Udedi SC, Nwaka AC, et al. *Phytochemical test methods: qualitative, quantitative and proximate analysis*. In: Egbuna C, Ifemeje JC, Udedi SC, Kumar S, editors. *Phytochemistry. Vol. 1: Fundamentals, methods and applications*. New York: Apple Academic Press; 2018. p. 381-425.
 56. Egbuna C, Tupas GD, editors. *Functional foods and nutraceuticals: bioactive components, formulations and innovations*. Cham: Springer Nature; 2020.
 57. Egbuna C, G?man MA, Jeevanandam J, editors. *Applications of nanotechnology in drug discovery and delivery*. Cambridge: Elsevier; 2021.
 58. Egbuna C, Sawicka B, editors. *Natural remedies for pest, disease and weed control*. London: Academic Press; 2019.
 59. Patrick-Iwuanyanwu KC, Obasi MO, Ogbo AO, Egbuna C. Human health risk assessment of heavy metals via consumption of selected seafoods from Bayelsa State. *Ann Biol Sci*. 2020;8(1):1-9.
 60. Orajiaka-Uchegbu C, Patrick-Iwuanyanwu KC, Ogbo BA, Egbuna C. Bioaccumulation of heavy metals and potential health risk through

- consumption of seafoods from selected creeks in Rivers State, Nigeria. *Egypt J Aquat Biol Fish.* 2020;24(7):1033-1053.
61. Chander V, Sharma B, Negi V, Aswal RS, Singh P, Singh R, et al. Pharmaceutical compounds in drinking water. *J Xenobiot.* 2016;6(1):5774.
 62. Chen Y, Zhang J. Development of point-of-care analytical devices for rapid drug detection. *Biosens Bioelectron.* 2024;236:115498.
 63. Gao Y, Wang X. Advances in solid phase extraction for bioanalysis. *J Chromatogr B.* 2023;1216:123507.
 64. Kumar S, Sharma R. LC–MS/MS approaches in pharmacokinetic modeling. *J Pharm Biomed Anal.* 2024;227:115275.
 65. Gupta V, Verma N. Modern approaches in bioanalytical method validation. *Bioanalysis.* 2023;15(8):569-585.
 66. Zhang L, Xu X. Microfluidic platforms for pharmaceutical bioanalysis. *Anal Chim Acta.* 2024;1258:341330.
 67. Patel R, Singh D. Advances in dried blood spot sampling for pharmacokinetic studies. *J Pharm Biomed Anal.* 2023;221:115089.
 68. Zhao Q, Chen Y. Hybrid LC–MS techniques for oligonucleotide bioanalysis. *J Chromatogr B.* 2025;1221:123610.
 69. Brown T, Smith A. Emerging analytical platforms in pharmaceutical bioanalysis. *Trends Anal Chem.* 2023;161:116988.
 70. Kumar P, Singh R. Analytical challenges in LC–MS/MS bioanalysis of complex matrices. *Anal Chem.* 2025;97(4):2348-2362.
 71. Patel A, Desai P. Advanced chromatographic techniques for drug quantification. *J Pharm Biomed Anal.* 2023;223:115145.
 72. Li H, Wang Y. Biosensor technologies for point-of-care pharmaceutical analysis. *Biosens Bioelectron.* 2024;234:115413.
 73. Chen L, Zhao M. Microfluidic analytical systems in clinical diagnostics. *Anal Chim Acta.* 2023;1241:340447.
 74. Singh V, Patel R. Advances in nanobiosensors for therapeutic drug monitoring. *Talanta.* 2024;257:124486.
 75. Sharma N, Gupta P. Analytical strategies for metabolite identification using LC–MS. *J Chromatogr B.* 2023;1219:123552.
 76. Desai K, Patel J. Advanced sample preparation techniques for pharmaceutical bioanalysis. *Talanta.* 2023;248:123648.
 77. Ahmed S, Khan M. LC-MS-based bioanalytical methods in pharmacokinetic studies. *Bioanalysis.* 2023;15(10):721-736.
 78. Thomas J, Walker P. Advances in therapeutic protein bioanalysis. *Anal Chim Acta.* 2024;1249:340912.
 79. Chandra S, Gupta R. Ultra-performance liquid chromatography in pharmaceutical analysis. *J Pharm Biomed Anal.* 2023;224:115168.
 80. Kumar N, Verma A. Green analytical chemistry approaches in bioanalysis. *Trends Anal Chem.* 2024;163:117005.
 81. Singh R, Gupta S. Bioanalytical approaches for monoclonal antibody quantification. *Bioanalysis.* 2024;16(6):405-421.
 82. Lee S, Kim D. LC–MS techniques in clinical pharmacokinetics. *J Chromatogr B.* 2023;1209:123391.
 83. Chen Y, Li F. Quantitative bioanalysis using LC–MS/MS. *Talanta.* 2023;250:123721.
 84. Zhao H, Wang J. Chromatographic separation of pharmaceuticals in biological matrices. *J Pharm Biomed Anal.* 2024;230:115358.
 85. Brown M, Carter D. Analytical strategies in drug metabolism studies. *Bioanalysis.* 2024;16(8):587-601.
 86. Gupta A, Singh P. Advances in SPE for pharmaceutical analysis. *Talanta.* 2023;251:123752.
 87. Patel V, Shah N. Microextraction techniques for drug determination. *Anal Chim Acta.* 2024;1251:341010.
 88. Wang T, Li H. LC–MS/MS in metabolite identification. *J Chromatogr B.* 2023;1210:123400.
 89. Fediuk DJ, Nucci G, Dawra VK, Cutler DL, Amin NB, Terra SG, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitor. *Clin Pharmacokinet.* 2020;59:949-965. doi:10.1007/s40262-020-00875-1.
 90. Kadokura T, Zhang W, Krauwinkel W, Leeftang S, Keirns J, Taniuchi Y, et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. *Clin Pharmacokinet.* 2014;53:975-988. doi:10.1007/s40262-014-0180-z.
 91. Zhang J, Cai LJ, Peng WX, Zhu RH, Yang J, Zhang QZ. Effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and development of a UPLC-MS/MS method. *J Clin Pharm Ther.* 2012;37:95-99. doi:10.1111/j.1365-2710.2011.01257.x.
 92. Dan S, Mandal P, Ghosh B, Barma S, Bose R, Pal T. Simultaneous determination of metformin and teneligliptin in human plasma by LC-ESI-MS/MS

- and its application to pharmacokinetic studies. *Indian Drugs*. 2018;55.
93. Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. Pharmacological and pharmacokinetic profile of teneligliptin: implications for clinical practice. *Drugs*. 2019;79:733-750. doi:10.1007/s40265-019-01086-0.
 94. Fernandez E, Ross C, Liang H, Javors M, Tardif S, Salmon AB. Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset. *Pharm Biol*. 2019;9:1657756. doi:10.1080/20010001.2019.1657756.
 95. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. *Drugs*. 2000;59:521-549. doi:10.2165/00003495-200059030-00012.
 96. Choi HK, Oh M, Kim EJ, Song GS, Ghim JL, Shon JH, et al. Pharmacokinetic study comparing voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. *Int J Clin Pharmacol Ther*. 2015;53:147-153. doi:10.5414/cp202197.
 97. Hess C, Musshoff F, Madea B. Simultaneous identification and quantification of oral hypoglycaemic drugs in plasma by LC-MS. *Anal Bioanal Chem*. 2011;400:33-41. doi:10.1007/s00216-011-4698-8.
 98. Welling PG, Patel RB, Patel UR, Gillespie WR, Craig WA, Albert KS. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. *J Pharm Sci*. 1982;71:1259-1263. doi:10.1002/jps.2600711119.
 99. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med*. 2005;355:487-497. doi:10.1056/NEJMr050100.
 100. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. *Am J Med*. 2005;118:27S-34S. doi:10.1016/j.amjmed.2005.04.012.
 101. Fürthauer J, Flamm M, Sönnichsen A. Patient and physician related factors affecting adherence to evidence-based guidelines in diabetes mellitus type 2 and cardiovascular disease. *BMC Fam Pract*. 2013;14:47. doi:10.1186/1471-2296-14-47.
 102. Pednekar PP, Agh T, Malmenas M, Raval AD, Bennett BM, Borah BJ, et al. Methods for measuring multiple medication adherence: systematic review. *Value Health*. 2019;22:139-156. doi:10.1016/j.jval.2018.08.006.
 103. Tanna S, Lawson G. Dried blood spot analysis to assess medication adherence and personalize treatment. *Bioanalysis*. 2014;6:2825-2838. doi:10.4155/bio.14.189.
 104. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: methodological issues and cardiovascular outcomes. *J Hypertens*. 2017;35:1133-1144. doi:10.1097/HJH.0000000000001299.
 105. Anghel LA, Farcas AM, Oprean RN. Overview of common methods used to measure treatment adherence. *Med Pharm Rep*. 2019;92:117-122. doi:10.15386/mpr-1201.
 106. Lam WY, Fresco P. Medication adherence measures: an overview. *Biomed Res Int*. 2015;2015:217047. doi:10.1155/2015/217047.
 107. Mechler K, Häage A. Drugs don't work in patients who don't take them. *Z Kinder Jugendpsychiatr Psychother*. 2019;47:528-534. doi:10.1024/1422-4917/a000645.
 108. Cajka T, Fiehn O. Toward merging untargeted and targeted methods in mass spectrometry-based metabolomics and lipidomics. *Anal Chem*. 2016;88:524-545. doi:10.1021/acs.analchem.5b04491.
 109. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: position statement of the American Diabetes Association. *Diabetes Care*. 2017;40:1273-1284. doi:10.2337/dci17-0026.
 110. Maki KC, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: clinical implications. *Postgrad Med*. 2018;130:166-172. doi:10.1080/00325481.2018.1402658.